CYTARABINE INJECTION 100 MG — DIN 02126656
CYTARABINE : 100 MG · PFIZER CANADA ULC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CYTARABINE INJECTION?
CYTARABINE INJECTION 100 MG contains CYTARABINE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02126656, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS ; INTRATHECAL administration. Health Canada currently lists it as marketed, status dated 12-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CYTARABINE INJECTION used for?
Induction and maintenance of remission in acute leukemia (myelocytic, lymphocytic, erythroleukemia) and chronic myelocytic leukemia (blast phase). Also for non-Hodgkin's lymphoma in children.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cytarabine cost around the world?
Cytarabine is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 9 | 12 | SAR███.██ |
| South Africa | single exit price | 10 | 10 | ZAR███.██ |
| Morocco | PPV (public price) | 2 | 7 | MAD███.██ |
| Czechia | max producer price (ex-factory) | 3 | 5 | CZK███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
42 pack listings across 31 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Cytarabine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cytarabine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Cytarabine, across 19 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 8 | 1 | CYTOSAR, PMS-CYTARABINE | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | CYTARABINE INJECTION | Sourceable in Canada |
| STERIMAX INC | 1 | 1 | CYTARABINE INJECTION | Sourceable in Canada |
| NOVOPHARM LIMITED | 4 | 0 | CYTARABINE - PWS 1GN/VIAL, CYTARABINE - PWS 2GM/VIAL, CYTARABINE - PWS 500MG/VIAL, CYTARABINE-PWS 100MG/VIAL | No marketed DIN |
| AGILA JAMP CANADA INC | 1 | 0 | AJ-CYTARABINE | No marketed DIN |
| DAVID BULL LABORATORIES (PTY) LTD. | 1 | 0 | CYTARABINE INJ 100MG/ML | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | CYTARABINE INJECTION, MYLAN STD. | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | CYTARABINE INJECTION BP | No marketed DIN |
| SKYEPHARMA INC. | 1 | 0 | DEPOCYT | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS ; SUBCUTANEOUS ; INTRATHECAL |
| Pack configuration (monograph) | 100 mg/mL (available as 100 mg/mL, 1 g / 10 mL, 2 g / 20 mL) vials. |
| Storage | Store at 15-30°C. Protect from light. (Note: General summary based on standard practice as specific text was truncated). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cytarabine |
|---|---|
| ATC code | L01BC01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02126656 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2126656 |
| Brand name | CYTARABINE INJECTION |
| Generic / active ingredient | CYTARABINE : 100 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | L01BC01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01BC |
| Current status | MARKETED |
| Status date | 12-Sep-2017 |
| Original market date | 1996-09-23 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Induction/maintenance: 100-200 mg/m²/day by continuous IV infusion or rapid injection. High dose: 2-3 g/m² IV every 12 hours for 2-6 days. Also used SC and intrathecally.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug. Anaphylactic reactions have occurred.
Warnings and precautions
Potent bone marrow suppressant. High doses associated with severe CNS, GI, and pulmonary toxicity. Avoid benzyl alcohol in high-dose or intrathecal use. Monitor blood counts regularly.
Is Cytarabine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC (Tier 3 Drug Shortages About & Resources), last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYTARABINE INJECTION | 100 MG | SOLUTION | STERIMAX INC | MARKETED | 02515296 |
| PMS-CYTARABINE | 100 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02406772 |
| AJ-CYTARABINE | 100 MG | SOLUTION | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | 02404397 |
| CYTARABINE - PWS 1GN/VIAL | 1 G | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02167883 |
| CYTARABINE - PWS 2GM/VIAL | 2 G | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02167891 |
| CYTARABINE - PWS 500MG/VIAL | 500 MG | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02167875 |
| CYTARABINE INJ 100MG/ML | 100 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 00885797 |
| CYTARABINE INJECTION BP | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02394901 |
| CYTARABINE INJECTION, MYLAN STD. | 100 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | 02402203 |
| CYTARABINE-PWS 100MG/VIAL | 100 MG | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02167867 |
2 · Same class — other molecules in ATC L01BC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Capecitabine | ACH-CAPECITABINE · APO-CAPECITABINE · CAPECITABINE · MINT-CAPECITABINE · +4 more | 20 | 11 | Yes |
| Azacitidine | AZACITIDINE FOR INJECTION · NAT-AZACITIDINE · ONUREG · PMS-AZACITIDINE FOR INJECTION · +2 more | 14 | 7 | Yes |
| Fluorouracil | ADRUCIL · ADRUCIL INJ 50MG/ML · EFUDEX · FLUOROPLEX CREAM 1% · +4 more | 15 | 6 | Yes |
| Cytarabine | AJ-CYTARABINE · CYTARABINE - PWS 1GN/VIAL · CYTARABINE - PWS 2GM/VIAL · CYTARABINE - PWS 500MG/VIAL · +8 more | 19 | 3 | Yes |
| Gemcitabine | ACT GEMCITABINE · AJ-GEMCITABINE · GEMCITABINE FOR INJECTION · GEMCITABINE FOR INJECTION CONCENTRATE · +7 more | 38 | 2 | Yes |
| Trifluridine, Combinations | LONSURF | 2 | 2 | Yes |
| Decitabine | DACOGEN · DEMYLOCAN | 2 | 1 | Yes |
| Fluorouracil, Combinations | ACTIKERALL | 1 | 1 | Yes |
| Decitabine, Combinations | INQOVI | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01BA | Methotrexate · Pemetrexed · Pralatrexate% · Raltitrexed | 90 | 36 |
| L01BB | Cladribine · Clofarabine · Fludarabine · Mercaptopurine · Nelarabine · +1 more | 18 | 10 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CYTARABINE INJECTION called?
The same molecule, Cytarabine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ARACYTINE | Latin | Morocco |
| ALEXAN | Latin | Czechia |
| CYTARABINE ACCORD | Latin | Czechia |
| CYTARABINE EBEWE | Latin | Morocco |
| Pfizer Australia Pty Ltd | Latin | Australia |
| VYXEOS LIPOSOMAL | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.